HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by O’Brien, S. Search for Related Content PubMed PubMed Citation Articles by O’Brien, S. Social Bookmarking                   What's this?

New Agents in the Treatment of CLL

Correspondence: Susan O’Brien, MD, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 428, Houston, TX 77030; Phone: 713-792-7543; Fax: 713-794-4297; e-mail: sobrien{at}mdanderson.org.

Abstract

Chemoimmunotherapy has resulted in high complete remission rates and long remission duration in patients with chronic lymphocytic leukemia (CLL) but relapses occur and curative strategies still need to be developed. A wealth of new agents with a wide variety of mechanisms of action against CLL are currently in clinical trials. Twelve of these agents, which are in various stages of development varying from Phase I to Phase III trials, will be discussed. These include alkylating agents, monoclonal antibodies, immune modulators, cyclin-dependent kinase (CDK) inhibitors, BCL-2 family member inhibitors, protein kinase C (PKC) inhibitors, SRC inhibitors, HSP-90 inhibitors and small modular immune pharmaceutics (SMIP).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?